Camrelizumab

Monoclonal antibody

Also known as SHR-1210

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USNasopharyngeal Carcinoma · Phase 3 · investigational in the USCervical Cancer · Phase 2/3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US

Also approved (8)
CN
  • Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior bevacizumab, with famitinib (conditional approval)
  • First-line unresectable or metastatic hepatocellular carcinoma, with apatinib
  • First-line locally advanced or metastatic squamous NSCLC, with carboplatin + paclitaxel
  • First-line locally relapsed or metastatic nasopharyngeal carcinoma, with cisplatin + gemcitabine
  • Advanced nasopharyngeal carcinoma progressed after or intolerable to second-line or later chemotherapy
  • First-line unresectable locally advanced or metastatic EGFR-negative, ALK-negative non-squamous NSCLC, with pemetrexed + carboplatin
  • Advanced hepatocellular carcinoma after sorafenib and/or oxaliplatin-containing chemotherapy
  • Relapsed or refractory classic Hodgkin lymphoma after at least two systematic therapies (conditional approval; first approval)
Product first approved 2019hengrui.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (45)
Gastric Cancer
NCT05610332 · Fujian Medical University
2022-11-01 – 2027-11-01 · Locally Advanced Gastric Cancer
What this study did
NCT04342910 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-21 – 2026-09-01 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06172205 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2029-07-31 · BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
What this study did
NCT06485466 · Guohui Xu
2024-08-10 – 2028-06-30 · Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
What this study did
NCT05738616 · Wen Tianfu
2024-05-10 – 2027-12-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT04639180 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-01 – 2026-07-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05320692 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-09 – 2026-07-30 · Hepatocellular Carcinoma
What this study did
NCT05313282 · Sun Yat-sen University
2022-06-15 – 2025-06-01 · C-staged Hepatocellular Carcinoma in BCLC Classification
What this study did
NCT03605706 · Jiangsu HengRui Medicine Co., Ltd.
2019-05-31 – 2023-12 · Advanced Hepatocellular Carcinoma
What this study did
NCT04985136 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-26 – 2021-12-29 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
Nasopharyngeal Carcinoma
NCT06669611 · Sun Yat-sen University
2024-11-27 – 2029-11-20 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT06438627 · XIANG YANQUN
2024-05-30 – 2029-05-30 · Nasopharyngeal Carcinoma
What this study did
NCT04453826 · Sun Yat-sen University
2020-09-01 – 2028-09 · Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
What this study did
NCT05772208 · Fudan University
2022-01-01 – 2028-01-01 · Nasopharyngeal Carcinoma
What this study did
NCT05854849 · Sun Yat-sen University
2023-05-01 – 2027-12-01 · Nasopharyngeal Carcinoma
What this study did
NCT03427827 · Sun Yat-sen University
2018-07-02 – 2026-02 · Nasopharyngeal Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT04768075 · Guangdong Association of Clinical Trials
2021-05-28 – 2026-04-30 · Non-Small-Cell Lung Cancer
What this study did
NCT05042375 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-08 – 2025-12-31 · Non-small Cell Lung Cancer
What this study did
NCT04203485 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-15 – 2022-05-31 · PD-L1 Positive Non-small Cell Lung Cancer
What this study did
NCT03668496 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-09 – 2021-12-31 · Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody, Chemotherapy Effect
What this study did
Other / comorbidity
NCT07432087 · Yue He, MD
2026-02-01 – 2033-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT07267806 · Linhui Peng
2025-10-31 – 2032-10 · Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
What this study did
NCT06533384 · Guangdong Provincial People's Hospital
2024-08-01 – 2030-12-31 · Triple-negative Breast Cancer
What this study did
NCT05043688 · Zhigang Li
2021-09-01 – 2030-12-31 · Resectable Esophageal Squamous Cell Carcinoma
What this study did
NCT07948317 · Xuekui Liu
2027-01-01 – 2030-01-01 · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer
What this study did
NCT06229041 · Peking University Cancer Hospital & Institute
2023-03-29 – 2029-10-01 · Rectal Cancer
What this study did
NCT06889688 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-02-21 – 2029-06-01 · Breast Cancer Stage IV, Triple -Negative Breast Cancer
What this study did
NCT04928807 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-07-20 – 2028-03-20 · Rectal Cancer
What this study did
NCT05999149 · Fudan University
2023-08-20 – 2027-08-30 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT05789043 · Peking University Cancer Hospital & Institute
2023-03-21 – 2027-02-15 · Acral Melanoma
What this study did
NCT05760378 · Fudan University
2023-03-17 – 2027-01-01 · Triple-Negative Breast Cancer
What this study did
NCT05798793 · Hospital of Stomatology, Wuhan University
2023-11-21 – 2026-10-01 · Oral Squamous Cell Carcinoma
What this study did
NCT04613674 · Jiangsu HengRui Medicine Co., Ltd.
2020-12-09 – 2024-03-05 · Triple Negative Breast Cancer
What this study did
NCT04342936 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-17 – 2023-12-01 · Classical Hodgkin Lymphoma
What this study did
NCT04426955 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-30 – 2023-12 · Esophageal Cancer
What this study did
NCT05134194 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-01-17 – 2022-12-15 · Triple Negative Breast Cancer
What this study did
NCT03691090 · Jiangsu HengRui Medicine Co., Ltd.
2018-12-03 – 2022-04-30 · Advanced Esophageal Cancer
What this study did
NCT04490421 · Fuzhou General Hospital
2020-08-01 – 2022-02-01 · Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
What this study did
NCT03099382 · Jiangsu HengRui Medicine Co., Ltd.
2017-05-05 – 2019-05-06 · Esophageal Carcinoma
What this study did
Phase 2/3 (13)
Cervical Cancer
NCT06288373 · Tongji Hospital
2024-04-22 – 2031-03-01 · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
What this study did
Gastric Cancer
NCT04208347 · Ruijin Hospital
2019-12-18 – 2027-12 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT06739317 · Sun Yat-sen University
2025-01-01 – 2031-06-30 · Unresectable Hepatocellular Carcinoma (HCC)
What this study did
NCT06796803 · Shanghai Zhongshan Hospital
2025-02-20 – 2030-02-28 · Potentially Resectable Hepatocellular Carcinoma
What this study did
NCT05062837 · Guangxi Medical University
2021-06-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT04521153 · Shanghai Zhongshan Hospital
2021-03-25 – 2026-03-01 · Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
What this study did
NCT04909866 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-01-01 – 2022-12-01 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT04803539 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-01 – 2033-09-01 · Breast Cancer
What this study did
NCT07589244 · Guangzhou Virotech Pharmaceutical Co., Ltd.
2026-05-13 – 2029-06-30 · HCC
What this study did
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06361888 · Hutchmed
2024-05-08 – 2028-05-31 · Metastatic Pancreatic Cancer
What this study did
NCT04907344 · Tianjin Medical University Cancer Institute and Hospital
2021-06-15 – 2025-06-30 · Triple Negative Breast Cancer
What this study did
NCT04510610 · Chinese PLA General Hospital
2019-09-01 – 2025-01-01 · Hodgkin Lymphoma
What this study did
Phase 2 (331)
Cervical Cancer
NCT06288360 · Tongji Hospital
2024-09-12 – 2030-12-12 · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
What this study did
NCT06289062 · Tongji Hospital
2024-05-08 – 2030-12-01 · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
What this study did
NCT07167160 · Women's Hospital School Of Medicine Zhejiang University
2025-03-10 – 2029-12-31 · Cervical Cancer, Immunochemotherapy
What this study did
NCT07627620 · Hunan Cancer Hospital
2026-06-30 – 2029-03-30 · Cervical Cancer
What this study did
NCT07143292 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-11-30 – 2028-06-30 · Cervical Cancer Metastatic, Cervical Cancer Recurrent
What this study did
NCT05311566 · Lei Li
2022-03-27 – 2026-03-27 · Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy, Immune Checkpoint Inhibitor, Survival Outcomes, Adverse Events, Early Stage Cervical Cancer, Locally Advanced Cervical Cancer
What this study did
NCT04680988 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-05 – 2025-07-07 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT05234905 · Zhejiang Cancer Hospital
2022-03 – 2024-12 · Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
What this study did
NCT04884906 · Tianjin Medical University Cancer Institute and Hospital
2020-11-01 – 2024-11-01 · Locally Advanced Cervical Cancer
What this study did
NCT05290935 · Lei Li
2022-03-13 – 2024-03-13 · Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors, Anti-PD-1 Antibody, Albumin-bound Paclitaxel
What this study did
NCT04974944 · Sun Yat-Sen University Cancer Center
2021-07-30 – 2024-01-08 · Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
What this study did
NCT05151549 · Hunan Cancer Hospital
2021-12-01 – 2023-12-12 · Cervical Cancer
What this study did
NCT04974827 · Hunan Cancer Hospital
2021-05-20 – 2023-05-20 · Cervical Cancer
What this study did
NCT03827837 · Jiangsu HengRui Medicine Co., Ltd.
2019-01-23 – 2022-12 · Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
What this study did
NCT03816553 · Sun Yat-sen University
2019-01-19 – 2022-08-31 · Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
What this study did
NCT04188860 · Lei Li
2019-12-06 – 2022-03-06 · Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody, Immunotherapy
What this study did
Gastric Cancer
NCT07026149 · Ruijin Hospital
2025-06-08 – 2030-05-31 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06693128 · Ruijin Hospital
2024-11-21 – 2027-12-31 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06711471 · LIN YANG
2024-11-14 – 2027-11-13 · Gastric Cancer Adenocarcinoma Metastatic
What this study did
NCT05524974 · Fujian Medical University
2022-09-01 – 2027-09-01 · Locally Advanced Gastric Cancer
What this study did
NCT03950271 · Henan Cancer Hospital
2020-01-20 – 2026-12-31 · Gastric Cancer
What this study did
NCT07320586 · Shandong Tumor Hospital
2021-03-01 – 2026-12-31 · Gastric Cancer, Second-line Therapy
What this study did
NCT05602935 · The Second Affiliated Hospital of Fujian Medical University
2020-09-16 – 2026-12-30 · Stomach Neoplasms, Digestive System Neoplasms, Neoplasms, Digestive System Diseases, Stomach Diseases, Neoplasms by Site
What this study did
NCT04515615 · Yu jiren
2020-09-09 – 2026-03-29 · Gastric Cancer Stage III
What this study did
NCT05669807 · Zhejiang Cancer Hospital
2022-12 – 2025-11 · Second Line Treatment of Gastric Cancer
What this study did
NCT05184946 · The Second Affiliated Hospital of Shandong First Medical University
2021-10-09 – 2025-10-08 · Gastric Cancer
What this study did
NCT04781686 · Zhou Fuxiang
2021-05-14 – 2025-08 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05410847 · Hebei Medical University
2022-06-30 – 2025-06-30 · Gastric Cancer
What this study did
NCT04195828 · Fujian Medical University
2020-06-18 – 2025-03-24 · Advanced Gastric Cancer
What this study did
NCT04510064 · Fudan University
2021-01-06 – 2024-07-31 · Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
What this study did
NCT03939962 · Henan Cancer Hospital
2019-07-24 – 2024-05-30 · Gastric Cancer
What this study did
NCT05070598 · Shengjing Hospital
2021-09-07 – 2024-03-30 · HER2-positive Gastric Cancer
What this study did
NCT04631757 · Tianjin Medical University Cancer Institute and Hospital
2020-12-15 – 2023-12-31 · Gastric Cancer
What this study did
NCT04294784 · Huazhong University of Science and Technology
2020-04-03 – 2023-11-30 · Gastric Cancer, GastroEsophageal Cancer
What this study did
NCT05342389 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-05-01 – 2023-11-01 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05095636 · Fudan University
2021-03-17 – 2023-09 · Gastric Cancer, Metastasis
What this study did
NCT05545436 · Third Affiliated Hospital, Sun Yat-Sen University
2022-09-20 – 2023-06 · Locally Advanced Gastric Cancer
What this study did
NCT04694183 · Quan Wang
2020-08-17 – 2023-05-06 · Stomach Neoplasms
What this study did
NCT04367025 · Chinese PLA General Hospital
2020-05 – 2023-05 · Gastric Cancer
What this study did
NCT04258644 · Beijing Friendship Hospital
2020-03-01 – 2023-02-28 · Gastric Cancer
What this study did
NCT04792515 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2022-12-31 · Locally Advanced Gastric Cancer
What this study did
NCT04152889 · RenJi Hospital
2020-04-14 – 2022-12 · Gastric Cancer Stage III
What this study did
NCT04345783 · Beijing Friendship Hospital
2018-01-01 – 2022-06-30 · Gastric Cancer
What this study did
NCT03755440 · Sun Yat-sen University
2018-12-01 – 2020-12-31 · Gastric Cancer Stage IV, EBV
What this study did
NCT03472365 · Jiangsu HengRui Medicine Co., Ltd.
2018-04-02 – 2020-11-25 · Gastric Cancer, GastroEsophageal Cancer
What this study did
Hepatocellular Carcinoma
NCT07328009 · Fudan University
2026-01-19 – 2029-01-15 · Hepato Cellular Carcinoma (HCC)
What this study did
NCT07324473 · First Affiliated Hospital of Chongqing Medical University
2026-01-01 – 2029-01-01 · Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
What this study did
NCT07314372 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-02-01 – 2028-12 · Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
What this study did
Phase 1/2 (40)
Gastric Cancer
NCT05101616 · Shanghai Minimally Invasive Surgery Center
2022-07-01 – 2027-01-01 · Gastric Cancer
What this study did
NCT04572542 · The First Affiliated Hospital of Xiamen University
2020-01-01 – 2022-06-01 · Locally Advanced or Metastatic Gastric Adenocarcinoma
What this study did
NCT04182724 · Chinese PLA General Hospital
2019-11-12 – 2022-05-12 · Advanced Gastric Cancer
What this study did
NCT04067986 · Zhongshan Hospital Xiamen University
2019-08-20 – 2021-10-31 · Colorectal Cancer Recurrent
What this study did
NCT04286711 · China Medical University, China
2020-03 – 2021-06 · Advanced Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06124001 · CNBG-Virogin Biotech (Shanghai) Ltd.
2023-11-30 – 2026-06-30 · Primary Hepatocellular Carcinoma
What this study did
NCT05924997 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2026-06-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT04443309 · Peking Union Medical College Hospital
2020-09-11 – 2024-08 · Hepatocellular Carcinoma
What this study did
NCT04997850 · Xinrui Zhu,MD
2020-10-01 – 2024-01-31 · Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
What this study did
NCT05042336 · Sichuan University
2021-09-01 – 2023-10-01 · Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma
What this study did
NCT04035876 · Zhejiang University
2019-07-16 – 2021-12-31 · Hepatocellular Carcinoma, Liver Transplant
What this study did
NCT02942329 · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
2016-10 – 2018-10 · Gastric Cancer, Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04133337 · Sichuan Cancer Hospital and Research Institute
2019-11-01 – 2021-06 · Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-small-cell Lung Cancer
What this study did
NCT03601598 · Harbin Medical University
2018-07-30 – 2020-07-30 · CRC, HCC, NSCLC
What this study did
Other / comorbidity
NCT05981001 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-04-30 · Breast Neoplasms
What this study did
NCT07587034 · Shanghai Zhongshan Hospital
2026-06 – 2029-12 · Liver Cancer
What this study did
NCT07662681 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-07-01 – 2029-07-01 · Head and Neck Cancer
What this study did
NCT05983237 · Jun Guo
2023-08-15 – 2027-12-31 · Melanoma
What this study did
NCT07161791 · Harbin Medical University
2025-09-15 – 2027-12-31 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT06376721 · Beijing Tongren Hospital
2024-04-14 – 2027-10-31 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma
What this study did
NCT04706598 · Fudan University
2021-06-09 – 2026-12 · Urinary Bladder Neoplasms, Immunotherapy
What this study did
NCT05176002 · Fujian Medical University Union Hospital
2021-11-10 – 2026-11 · Esophageal Neoplasm, Immunotherapy, Radiotherapy
What this study did
NCT04481763 · Jiangxi Provincial Cancer Hospital
2020-07-14 – 2026-10-01 · Triple-Negative Breast Cancer
What this study did
NCT06010212 · The First Affiliated Hospital with Nanjing Medical University
2023-08-25 – 2026-07-01 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05742750 · Sun Yat-sen University
2023-04-27 – 2026-05-30 · Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
What this study did
NCT04337606 · Chinese PLA General Hospital
2020-04-04 – 2026-04-04 · Non Hodgkin Lymphoma
What this study did
NCT05559008 · Ruijin Hospital
2022-09-30 – 2026-01-26 · Peripheral T Cell Lymphoma
What this study did
NCT04506138 · Zhejiang Cancer Hospital
2020-08-11 – 2025-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05218889 · Chinese PLA General Hospital
2021-08-04 – 2025-06 · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
What this study did
NCT05330065 · The First Affiliated Hospital of Zhengzhou University
2022-08-01 – 2024-08-31 · Malignant Pleural Effusion
What this study did
NCT04929652 · Jiangsu Cancer Institute & Hospital
2021-06-01 – 2024-06 · Advanced Colorectal Cancer
What this study did
NCT04231552 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2019-11-10 – 2023-09-30 · Rectal Cancer, Radiotherapy, Immunotherapy
What this study did
NCT04476459 · Huiqiang Huang
2020-07-23 – 2023-08-01 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT04298320 · Yanqiao Zhang
2020-03-15 – 2023-02-28 · Colorectal Cancer
What this study did
NCT04213898 · Henan Cancer Hospital
2020-01 – 2023-01 · Triple-negative Breast Cancer
What this study did
NCT04201990 · ShiYue Li
2019-12 – 2022-12 · Lung Cancer
What this study did
NCT04044378 · Peking University People's Hospital
2019-08-15 – 2022-09-30 · Effect of Drugs, Progression, Pediatric Cancer
What this study did
NCT04202978 · Zhongshan Hospital Xiamen University
2020-03-01 – 2021-11-01 · Hepatic Metastasis of Colorectal Cancer
What this study did
NCT03171220 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2017-06-01 – 2020-12-31 · Advanced Malignant Solid Tumor
What this study did
NCT03346642 · Chinese PLA General Hospital
2017-05-01 – 2019-10-01 · Primary Mediastinal Large B-cell Lymphoma
What this study did
Phase 1 (28)
Cervical Cancer
NCT04508686 · Ruijin Hospital
2020-08-01 – 2024-08-01 · Advanced Cervical Cancer
What this study did
Hepatocellular Carcinoma
NCT05031949 · Zhang Bi Xiang, MD
2021-10-30 – 2025-06-30 · Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable, Hyperbaric Oxygen Therapy
What this study did
NCT04564313 · Third Affiliated Hospital, Sun Yat-Sen University
2020-09-21 – 2023-07 · Hepatocellular Carcinoma, Liver Transplantation
What this study did
Nasopharyngeal Carcinoma
NCT03121716 · Jiangsu HengRui Medicine Co., Ltd.
2017-04-26 – 2020-07-31 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT03527251 · Sun Yat-sen University
2018-05-15 – 2019-12-31 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06121557 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-01 – 2031-12-31 · Breast Neoplasms
What this study did
NCT06654297 · West China Hospital
2024-10-27 – 2027-02-07 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06530082 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-12-01 – 2027-01-01 · Breast Neoplasms
What this study did
NCT06326736 · Jinling Hospital, China
2024-04 – 2026-12 · Pancreatic Cancer
What this study did
NCT06109207 · West China Hospital
2023-10-31 – 2025-10-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04932187 · Ruijin Hospital
2021-08-01 – 2025-07-01 · Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
What this study did
NCT04074564 · HRYZ Biotech Co.
2019-11-22 – 2024-12-05 · Sarcoma
What this study did
NCT05643417 · Fudan University
2022-12 – 2024-10 · Metastatic Liver Cancer
What this study did
NCT04510818 · Ruijin Hospital
2020-08-01 – 2024-08-01 · Head and Neck Cancer, Esophageal Squamous Cancer
What this study did
NCT05429398 · Shanghai YingLi Pharmaceutical Co. Ltd.
2022-06-30 – 2024-05-30 · Advanced Solid Tumor
What this study did
NCT05001412 · Zhou Chengzhi
2021-01-27 – 2024-01-25 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04393506 · Shanghai Jiao Tong University School of Medicine
2020-04-23 – 2023-11-10 · Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
What this study did
NCT05799183 · Jiangsu HengRui Medicine Co., Ltd.
2023-07-04 – 2023-10-12 · Advanced Tumors
What this study did
NCT03491631 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-20 – 2023-09 · Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
What this study did
NCT05198817 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-02-22 – 2023-06-30 · Advanced Malignant Tumors
What this study did
NCT04625894 · Fudan University
2020-12 – 2023-06 · Oligometastatic Gastrointestinal Cancer
What this study did
NCT05019534 · West China Hospital
2021-08-15 – 2022-12-01 · BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
What this study did
NCT03871855 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-28 – 2021-06-21 · Advanced Solid Tumor
What this study did
NCT03945604 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-04 – 2021-02-09 · Triple Negative Breast Cancer
What this study did
NCT02738489 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-13 – 2020-01-08 · Advanced Melanoma
What this study did
NCT02721589 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-06 – 2019-11-17 · Advanced Solid Tumors
What this study did
NCT03182673 · Jiangsu HengRui Medicine Co., Ltd.
2017-07-24 – 2019-06-12 · Solid Tumor
What this study did
NCT02742935 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-27 – 2019-05-06 · Solid Tumor, Breast Cancer, Gastrointestinal Cancer
What this study did
Phase 4 (1)
Early phase / not applicable (33)
Cervical Cancer
NCT07466901 · Jin LI
2026-04-01 – 2030-08-31 · Cervical Cancer, Radical Surgery, Adjuvant Therapy
What this study did
Gastric Cancer
NCT04889768 · Zhejiang Cancer Hospital
2021-07-31 – 2025-07-31 · Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
What this study did
NCT05715632 · Tang-Du Hospital
2023-02-01 – 2025-03-01 · Gastric Cancer
What this study did
NCT04675866 · Henan Cancer Hospital
2020-08-17 – 2023-12-31 · Advanced Gastric Adenocarcinoma
What this study did
NCT04174339 · Fujian Cancer Hospital
2019-12-10 – 2021-05-02 · Advanced Gastric Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT04559607 · Zhongda Hospital
2020-09-11 – 2026-01-31 · Hepatocellular Carcinoma
What this study did
NCT06061276 · Sun Yat-sen University
2024-05-20 – 2025-12-30 · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab, Lenvatinib
What this study did
NCT04487704 · First Affiliated Hospital Xi'an Jiaotong University
2020-04-07 – 2025-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT03722875 · Shanghai Zhongshan Hospital
2018-12-01 – 2020-03-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07053215 · The First Hospital of Hebei Medical University
2020-12-01 – 2024-12-01 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT04970043 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-07-31 – 2024-07-30 · Lung Cancer Stage II
What this study did
NCT04950400 · Beijing Chest Hospital
2021-07-07 – 2024-04-04 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07491822 · Tianjin Medical University Cancer Institute and Hospital
2026-03-25 – 2031-03-15 · TNBC
What this study did
NCT06048926 · The First Affiliated Hospital with Nanjing Medical University
2022-07-30 – 2028-07-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05772273 · The First Affiliated Hospital of Soochow University
2023-03-15 – 2027-12-31 · Acute Myeloid Leukemia
What this study did
NCT05202314 · Beijing Chao Yang Hospital
2021-12-12 – 2026-12-30 · Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction, Immunotherapy
What this study did
NCT06636591 · Fudan University
2024-12-23 – 2026-06-30 · Breast Cancer Female, HER2-negative Breast Cancer
What this study did
NCT05380986 · Henan Cancer Hospital
2022-05-20 – 2025-05-01 · Solid Tumor
What this study did
NCT05583383 · Henan Cancer Hospital
2022-03-31 – 2025-03-31 · Advanced Gastric Adenocarcinoma
What this study did
NCT04366128 · Rong Tao
2020-04-25 – 2024-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT05697237 · First Affiliated Hospital Xi'an Jiaotong University
2023-01 – 2024-12 · Cholangiocarcinoma
What this study did
NCT04782089 · Qilu Hospital of Shandong University
2021-05-06 – 2024-06-01 · Small Cell Lung Cancer
What this study did
NCT05600998 · Peking University Third Hospital
2022-10-30 – 2024-02-28 · Ovarian Clear Cell Carcinoma
What this study did
NCT05050760 · Xijing Hospital
2021-09-01 – 2023-12 · ESCC
What this study did
NCT04420130 · Yanqiao Zhang
2020-08-01 – 2023-08-01 · Pancreatic Cancer, Liver Metastasis
What this study did
NCT04741490 · Fuzhou General Hospital
2021-02 – 2023-08 · Esophageal Squamous Cell Carcinomas
What this study did
NCT04181645 · RenJi Hospital
2019-06-29 – 2023-05-01 · Pancreatic Cancer Stage IV
What this study did
NCT04654403 · The First Affiliated Hospital of Zhengzhou University
2022-01-01 – 2022-12-31 · Esophageal Cancer
What this study did
NCT04507750 · Qianfoshan Hospital
2020-08-10 – 2022-08-30 · Immune Checkpoint Inhibition
What this study did
NCT03671265 · Tianjin Medical University Cancer Institute and Hospital
2018-09-17 – 2021-09-01 · Esophageal Cancer
What this study did
NCT03222440 · Tianjin Medical University Cancer Institute and Hospital
2017-07-19 – 2019-11-01 · Esophageal Cancer
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (3)
Hepatocellular Carcinoma
NCT07309419 · Shanghai Zhongshan Hospital
2025-12-22 – 2030-06-30 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT05576272 · Qilu Pharmaceutical Co., Ltd.
2022-05-19 – 2024-12-30 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06335355 · Shanghai Shengdi Pharmaceutical Co., Ltd
2024-03 – 2030-10 · Non-squamous Non-small Cell Lung Cancer
What this study did
Appears in other studies (16)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Hepatocellular Carcinoma
NCT05613478 · The First Affiliated Hospital with Nanjing Medical University
2023-01-31 – 2027-11-01 · Hepatocellular Carcinoma, Immunotherapy, Preoperative
What this study did
NCT05198609 · Sun Yat-sen University
2022-01-17 – 2026-07-01 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT04944914 · Sun Yat-sen University
2021-06-01 – 2028-06-01 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04619433 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-01 – 2025-08-16 · Non-squamous Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT05049681 · Feng Wang
2021-12-05 – 2023-06-30 · Esophageal Cancer
What this study did
Phase 2 (8)
Hepatocellular Carcinoma
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT04930315 · Zhejiang University
2021-09-15 – 2026-04-30 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT04830267 · Chongqing University Cancer Hospital
2021-03-01 – 2026-08-01 · Nasopharyngeal Carcinoma
What this study did
Other / comorbidity
NCT07791602 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-06-12 – 2032-12 · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
What this study did
NCT06055166 · Chongqing University Cancer Hospital
2023-11-01 – 2026-05-31 · PARP Inhibitor for Esophageal Squamous Cell Carcinoma
What this study did
NCT05222035 · Sun Yat-sen University
2022-01-24 – 2023-06-01 · PD-1 Inhibitor, G-CSF
What this study did
NCT03987698 · Tianjin Medical University Cancer Institute and Hospital
2019-06-01 – 2022-06-01 · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT06276933 · Tongji University
2024-02-22 – 2026-11-22 · Lung Cancer, Camrelizumab
What this study did
Early phase / not applicable (2)
Hepatocellular Carcinoma
NCT05339581 · RenJi Hospital
2022-05-20 – 2024-05-31 · Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications
What this study did
Other / comorbidity
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Camrelizumab: this drugPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(81 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Camrelizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (15)
November 2026 (1)
Phase 2Soft Tissue Sarcoma (STS), OsteosarcomaRecruiting
Est. primary completion 2026-11-30 · NCT07602049 · CT.gov ↗
What to watch
December 2026 (14)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07107217 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerActive not recruiting
Est. primary completion 2026-12 · NCT04208347 · CT.gov ↗
What to watch
Phase 2Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07530094 · CT.gov ↗
What to watch
Phase 2Gestational Trophoblastic NeoplasiaRecruiting
Est. primary completion 2026-12-01 · NCT05139095 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07143292 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05062837 · CT.gov ↗
What to watch
Phase 1Breast NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT06121557 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT05983237 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07161791 · CT.gov ↗
What to watch
Phase 2Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06831175 · CT.gov ↗
What to watch
Phase 2Hepatocellulcar CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07238881 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-31 · NCT07167160 · CT.gov ↗
What to watch
Phase 2ESCCRecruiting
Est. primary completion 2026-12-31 · NCT07808853 · CT.gov ↗
What to watch
Phase 3Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06533384 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
Phase 2Metastatic Pancreatic CarcinomaNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
Phase 2Unresectable Metastatic Rectal Cancer, CAPOX, Combination of RadioimmunotherapyNot yet recruiting
Est. primary completion 2027-01-30 · NCT07059949 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07618546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Germline BRCA-mutated HER2-negative Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05576389 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-01 · NCT05738616 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Triple Negative Breast Cancer (TNBC), Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT06731153 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT05772273 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07100392 · CT.gov ↗
What to watch
Phase 2Mixed Hepatocellular-cholangiocarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07105748 · CT.gov ↗
What to watch
September 2027 (2)
Early phase / not applicableTNBCNot yet recruiting
Est. primary completion 2027-09-15 · NCT07491822 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07627620 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Rectal CancerRecruiting
Est. primary completion 2027-10-01 · NCT06229041 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Esophageal Squamous Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-11-01 · NCT07312578 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-11-20 · NCT06669611 · CT.gov ↗
What to watch
December 2027 (15)
Phase 2Esophageal Squamour Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07191977 · CT.gov ↗
What to watch
Phase 2Endometrioid Endometrial CancerRecruiting
Est. primary completion 2027-12-01 · NCT06561308 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-22 · NCT07016126 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2027-12-30 · NCT07334483 · CT.gov ↗
What to watch
Phase 2Refractory Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07896096 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Advanced Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response, ChemotherapyRecruiting
Est. primary completion 2027-12-31 · NCT06811844 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07154082 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07314372 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07555860 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Unresectable Gallbladder CancerRecruiting
Est. primary completion 2027-12-31 · NCT06423170 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06196671 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2028-02-01 · NCT07527026 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-02-20 · NCT06796803 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Breast Cancer Triple Negative Breast CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT07471815 · CT.gov ↗
What to watch
Phase 2Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, CamrelizumabRecruiting
Est. primary completion 2028-03-31 · NCT07787273 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2/3Metastatic Pancreatic CancerRecruiting
Est. primary completion 2028-05-31 · NCT06361888 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1/2Head and Neck CancerRecruiting
Est. primary completion 2028-07-01 · NCT07662681 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-31 · NCT06172205 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch
December 2028 (7)
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-12-31 · NCT07505186 · CT.gov ↗
What to watch
Phase 2Late-stage Resectable Esophageal Squamous CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07622797 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07902713 · CT.gov ↗
What to watch
Phase 2/3HCCRecruiting
Est. primary completion 2028-12-31 · NCT07589244 · CT.gov ↗
What to watch
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
Phase 3Resectable Esophageal Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT05043688 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07790419 · CT.gov ↗
What to watch
2029 (7)
January 2029 (2)
Phase 3Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07948317 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity NeoplasmNot yet recruiting
Est. primary completion 2029-02 · NCT07400094 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (CRC)Not yet recruiting
Est. primary completion 2029-02-01 · NCT07395063 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Hepato Cellular Carcinoma (HCC), Chemotherapy EffectRecruiting
Est. primary completion 2029-10 · NCT07267806 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1/2Liver CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07587034 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06869226 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Early phase / not applicableCervical CancerNot yet recruiting
Est. primary completion 2030-04-01 · NCT07466901 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT06739317 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07432087 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 2/3Cervical CancerRecruiting
Est. primary completion 2031-03-01 · NCT06288373 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-04-10 · NCT06992336 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Rectal Cancer PatientsNot yet recruiting
Est. primary completion 2031-12-31 · NCT07521605 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 1/2Breast NeoplasmsRecruiting
Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

9 April 2027FDA action datePDUFA target action date for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Source ↗

Recent

5 November 2026Filing acceptedFDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC)
US, FDA · Source ↗
10 July 2026Complete response letterFDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗